Business Context and Reporting Period
This Form 8-K is a current report filed by Bristol-Myers Squibb Company on November 7, 2019. The filing addresses Item 8.01 (Other Events) regarding the extension of the expiration date for previously announced Exchange Offers and Consent Solicitations related to notes issued by Celgene Corporation.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or margins. The only specific financial figure disclosed relates to the debt restructuring transaction:
- Aggregate Principal Amount of New Notes: Up to $19,850,000,000.
Material Changes
The primary material change reported is the extension of the expiration date for the Exchange Offers and Consent Solicitations:
- Previous Expiration Date: November 8, 2019, at 5:00 p.m. New York City time.
- New Expiration Date: November 13, 2019, at 5:00 p.m. New York City time.
- Reason for Change: The transaction is conditioned upon the closing of the Merger with Celgene, which is expected to occur by the end of 2019. The date may be extended further if necessary.
Outlook, Risks, and Management Commentary
Transaction Details: The Exchange Offers allow holders of Celgene Notes to exchange them for new notes issued by Bristol-Myers Squibb and cash. The Consent Solicitations seek to adopt amendments eliminating substantially all restrictive covenants and certain events of default in the Celgene Notes indentures.
Conditions and Risks:
- The transaction is strictly conditioned upon the closing of the Merger, a condition that cannot be waived by Bristol-Myers Squibb.
- Supplemental indentures executed on May 1, 2019, will only become operative upon the settlement date of the Exchange Offers.
- The settlement date is expected to occur promptly after the Expiration Date and on or about the closing date of the Merger.
Investor Verification Checklist
- Verify the final closing date of the Bristol-Myers Squibb and Celgene Merger to confirm if the Exchange Offers will settle.
- Monitor for further press releases regarding additional extensions of the Expiration Date beyond November 13, 2019.
- Review the confidential offering memorandum and consent solicitation statement (dated April 17, 2019, as amended) for full terms of the new notes and amendments.
- Confirm the status of the $19.85 billion aggregate principal amount of new notes issuance.